Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S volume comparison study in healthy adults
NL-OMON50855Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and reactogenicity comparison and Non-inferiority of Day 28 antibody response. Started May 2021; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50855.